Human lives
drive our discovery
of microbiome therapeutics

Finch is a clinical-stage microbiome therapeutics company

leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs.

Human-First Discovery platform

Our platform is built to rapidly translate insights mined from compelling human data into the development of novel microbiome therapeutics.

Learn more


We are advancing a rich pipeline of investigational microbiome therapeutics designed to address a wide range of unmet medical needs, with a candidate in late-stage clinical development for recurrent C. difficile infection and candidates for inflammatory bowel disease and autism spectrum disorder in pre-clinical development.

Learn more

Recent news

Finch Therapeutics Provides Business Update

September 01, 2022

Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD

August 25, 2022

Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results

August 11, 2022

Join us

Join us in our mission to transform the lives of patients and families fighting serious medical conditions.

Learn more